All News Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
0.5097 ^USD	+4.83%		-2.17%	-2.43%

10/05	Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	MT
25/03	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	13/05	AQ
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	10/05	MT
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	10/05	NE
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	08/05	NE
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	06/05	NE
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12/04	AQ
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11/04	NE
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05/04	NE
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28/03	NE
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25/03	NE
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08/03	NE
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	09/02	MT
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	01/02	MT
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01/02	NE
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01/02	CI
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	01/02	NE
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	01/02	CI
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	18/11	AQ
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	09/11	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

All News

Filters